コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 entified using a combination of clinical and biologic markers.
2 the scoring systems through addition of new biologic markers.
3 cal activity indices in CD and with numerous biologic markers.
4 ctious complications, and prognostic role of biologic markers.
5 ed with specific clinical manifestations and biologic markers and may be a useful addition to the bio
7 a decrease in profibrotic and proangiogenic biologic markers, and upregulation of lung CXCL11 mRNA a
12 rapy and tested microbiologic, clinical, and biologic markers as prognostic indicators for clinical s
14 We recommend that treatment response and biologic markers be incorporated into the American Joint
16 ocused on mBC suggests that FMX-enhanced MRI biologic markers can be useful for pretherapy prediction
18 led to more pronounced beneficial effects in biologic marker expressions in pulmonary acute respirato
19 uggest that toenail samples provide a useful biologic marker for quantifying low-level arsenic exposu
20 inducible hsp70 in the model could provide a biologic marker for the prediction of clinical acute and
21 on (PDFF) is an accurate, reliable, and safe biologic marker for use in the noninvasive diagnosis of
22 othelial progenitor cells may be a surrogate biologic marker for vascular function and cumulative car
25 tments, and the advent of valid and reliable biologic markers hold promise in the coming decade for d
26 ds ratio analyses reinforced that a panel of biologic markers (IL-6, MMP-8) and bacteria (e.g., Bacte
27 We suggest that the use of such surrogate biologic markers in conjunction with F-cell numbers may
28 use of a combination of clinical factors and biologic markers is a promising strategy that needs to b
29 ntal diagnostic value over other imaging and biologic markers makes them easier to implement by other
32 by PTSD is corroborated using an independent biologic marker of immune response to infection, CMV-a t
34 onocytic MDSC ratio may represent a valuable biologic marker of lymph node involvement in patients wi
37 actor VIII, safety, expression kinetics, and biologic markers of AAV transduction for up to 3 years.
38 was to review known clinical predictors and biologic markers of adverse clinical outcomes in acute l
39 of reliable clinical and imaging predictive biologic markers of aggressiveness can contribute to pat
41 dy adjusted for C-reactive protein (CRP) and biologic markers of inflammation such as CRP, interleuki
45 t appropriate statistical methods to analyze biologic markers of stress, such as salivary cortisol, r
47 fferent high-risk groups, screening for both biologic markers provided better prognostic information
48 al response was correlated with amelioration biologic markers such as cytokine production (IFN-gamma,
52 aggressive lymphoma but clinically validated biologic markers that can predict natural history to tai
53 There are literally dozens of clinical and biologic markers that have been proposed as being predic
54 uantitative Western analysis, is a sensitive biologic marker to assess the short-term responsiveness
55 nfluence this variation and that addition of biologic markers to AJCC staging improves determination
56 suggesting a potential to develop surrogate biologic markers to identify the onset and progression o
58 e were calculated for clinical variables and biologic markers using the Cox model for multivariate an
60 injury occurs in scleroderma and provides a biologic marker whose relationship to disease activity a